KBC Securities - BIOTALYS NV (BTLS) Biotalys Manufacturing/commercialisation partnership for Evoca NG with Novonesis

Report

KBC Securities

Guy Sips

Biotalys Manufacturing/commercialisation partnership for Evoca NG with Novonesis

We welcome Biotalys and Novonesis announced a manufacturing and commercialisation partnership for Evoca NG. Leveraging Novonesis' world leading fermentation capabilities can not only add value to Biotalys' very promising Agrobody technology but (as Novonesis is one of the leaders in the field of biosolutions) this can as well be seen as an important step forward for Biotalys as they lay the foundation for future commercial launches from its Agrobody 2.0 technology platform. We reiterate our Buy rating and € 6.0 Target Price.

18/03/2024 1 EN

Underlying

BIOTALYS NV

See profile

BE0974386188 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Morning Notes : CPINV BB, OPTI BB, BTLS BB, ONWD BB

: CPINV BB, OPTI BB, BTLS BB, ONWD BB

March 18, 2024 March 18, 2024 1 EN

KBC Securities

Morning Notes : ARCAD NA, BESI NA, KIN BB, NEXTA BB, MTLS US, TINC BB, VGP BB, BTLS BB

: ARCAD NA, BESI NA, KIN BB, NEXTA BB, MTLS US, TINC BB, VGP BB, BTLS BB

February 22, 2024 February 22, 2024 1 EN

Materialise Medical segment continued to lead the way

We updated our Materialise model after 1Q24 revenues decreased 3% y/y as 1Q23 was an exceptionally strong quarter showing 24% growth. In 1Q24, Materialise's Medical segment continued to lead the way with 8% y/y revenue growth, while revenue declined in its Manufacturing and Software segments amidst less favourable market conditions. While continued investments in sustainable growth and the ongoing conversion to a recurring revenue business model impacted Materialise's operational profitability, they delivered a positive net result and an improved net cash position. We maintain our Buy rati...

April 26, 2024 April 26, 2024 1 EN

Wim Lewi

Wim Lewi

Xior 1Q24 Results show strong underlying performance, no JV deal

Xior 1Q24 EPRA EPS came far above our expectations at EUR 0.52 vs. 0.42 expected, thanks to a mix of factors: new assets + lfl growth, rental guarantees, cost savings and permitted hedging results. All these factors combined compensated the cost of debt increase to 3.18% (+88bps, bridge loan). The LTV came slightly below our expectation at 52.4% vs. 52.7% exp. The asset sale disposals advance with 100m closed and 220m committed, but Xior abandoned the route of a JV deal. The large asset sales like Naritaweg (A'dam) and the Zernike tower in Groningen are also no longer mentioned. FV impact of ...

April 26, 2024 April 26, 2024 1 EN

Sharad Kumar S.P

Sharad Kumar S.P

Quest for Growth Q1 FY24: Starting The Year With A €1.4m Net Loss

During 1Q24, Quest for Growth booked a net loss of –€1.4m while return on equity for the period was -1.0%. NAVps remained stable at €7.4ps (vs. €7.46ps during FY23-end). Within quoted assets, ABO Wind returned +42.0%, Tubize returned +25% and EVS Broadcasting returned +15% during 1Q24. Tubize and EVS are the largest positions in the portfolio as of 1Q24-end. On the other hand, LEM Holdings fell -18%, Melexis fell -18% and Equasens fell -16%; QfG added to their Equasens position during 1Q24. Harvia (saunas and sauna accessories) was a new addition to the listed portfolio and has returned +17.5...

April 26, 2024 April 26, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Biotalys Manufacturing/commercialisation partnership for Evoca NG with Novonesis

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : CPINV BB, OPTI BB, BTLS BB, ONWD BB

Morning Notes : ARCAD NA, BESI NA, KIN BB, NEXTA BB, MTLS US, TINC BB, VGP BB, BTLS BB

Materialise Medical segment continued to lead the way

Xior 1Q24 Results show strong underlying performance, no JV deal

Quest for Growth Q1 FY24: Starting The Year With A €1.4m Net Loss

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe